Your Health, We Care
Futibatinib is a substrate of CYP3A and P-gp.
Avoid concomitant use of drugs that are dual P-gp and strong CYP3A inhibitors with Futibatinib.
Concomitant use of drugs that are dual P-gp and strong CYP3A inhibitors with Futibatinib may increase futibatinib exposure, which may increase the incidence and severity of adverse reactions.
Avoid concomitant use of dual P-gp and strong CYP3A inducers with Futibatinib.
Concomitant use of drugs that are dual P-gp and strong CYP3A inducers may decrease futibatinib exposure, which may reduce the efficacy of Futibatinib.
Futibatinib is an inhibitor of P-gp and BCRP.
Consider more frequent monitoring for adverse reactions associated with concomitantly administered drugs that are sensitive substrates of P-gp or BCRP and reduce the dose of these drugs per their Prescribing Information.
Futibatinib may increase exposure of drugs that are substrates of P-gp or BCRP.
FDA，2022.09
